SpreeHealth
Drug price

Raloxifene: here's the fair price

This is what US pharmacies pay, on average, for raloxifene. Use it to spot a fair cash price, and feel good about asking for one.

Lowest generic tablet or capsule

Raloxifene Hcl 60 Mg Tablet

$6.62
pharmacy cost for 30

A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.

Your best move

Ask for generic Raloxifene Hcl 60 Mg Tablet. Pharmacies pay about $6.62 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.

Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.

Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.

Pharmacies near you

Your ZIP and location stay in your browser. We never store them.

Every strength and form

ProductPharmacy cost30 countEffective
RALOXIFENE HCL 60 MG TABLETGeneric$0.22
per tablet or capsule
$6.6210/21/2026

Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.

Label basics

What it is used for (FDA label)

1 INDICATIONS AND USAGE Raloxifene hydrochloride tablet, USP is an estrogen agonist/ antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. ( 1.1 ) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. ( 1.2 ). Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. ( 1.3 ) Important Limitations: Raloxifene hydrochloride is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer. ( 1.3 ) 1.1 Treatment and Prevention of Osteoporosis in Postmenopausal Women...

Boxed warning (from the label): WARNING: INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE WARNING: INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE Increased risk of deep vein thrombosis and pulmonary embolism have been reported with raloxifene hydrochloride tablets [see Warnings and Precautions ( 5.1 )]. Women with active or past history of venous thromboembolism should not take raloxifene hydrochloride tablets [see Contraindications ( 4.1 )]. Increased risk of death due to stroke occurred in a...

Common side effects (FDA label)

6 ADVERSE REACTIONS Adverse reactions (>2% and more common than with placebo) include: hot flashes, leg cramps, peripheral edema, flu syndrome, arthralgia, sweating.( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Cipla USA, Inc at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice....

Drug interactions (from the label)

7 DRUG INTERACTIONS Cholestyramine: Use with raloxifene hydrochloride tablets is not recommended. Reduces the absorption and enterohepatic cycling of raloxifene. ( 7.1 , 12.3 ) Warfarin: Monitor prothrombin time when starting or stopping Raloxifene hydrochloride tablets. ( 7.2 , 12.3 ) Highly Protein-Bound Drugs: Use with Raloxifene hydrochloride tablets with caution. Highly protein-bound drugs include diazepam, diazoxide, and lidocaine. Raloxifene hydrochloride is more than 95% bound to plasma proteins. ( 7.3 , 12.3 ) 7.1 Cholestyramine Concomitant administration of cholestyramine with raloxifene hydrochloride tablets is not recommended. Although not specifically studied, it is anticipated...

Warnings (from the label)

5 WARNINGS AND PRECAUTIONS Venous Thromboembolism: Increased risk of deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. Discontinue use 72 hours prior to and during prolonged immobilization. ( 5.1 , 6.1 ) Death Due to Stroke: Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. No increased risk of stroke was seen in this trial. Consider risk-benefit balance in women at risk for stroke. ( 5.2 , 14.5 ) Cardiovascular Diseas e: Raloxifene hydrochloride tablets should not be used for the primary or secondary prevention of cardiovascular disease. ( 5.3 , 14.5 )...

Source: FDA drug label via openFDA, label effective 2021-03-17. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.